From first-in-class science to clinical proof-of-concept, Kembi's programs are designed to address resistance across multiple tumour types.
KMB-464
Lead program
Phase 2
Most advanced stage
mTNBC
Lead indication
3
Active programs
Kembi's pipeline spans from active Phase 2 clinical trials to active discovery programs.
| Program | Indication | Modality | Stage | Status |
|---|---|---|---|---|
|
K4
KMB-464 (seviteronel) Lead compound |
mTNBC Metastatic triple-negative breast cancer |
Small molecule |
Phase 2
|
Ongoing
|
|
K4
KMB-464 Expansion |
Additional AR+ solid tumours |
Small molecule |
Preclinical
|
IND-enabling
|
|
K2
KMB-233 Next generation |
Confidential plasticity target |
Confidential |
Development
|
Active
|
KMB-464 (seviteronel)
Lead compound
KMB-464
Expansion
KMB-233
Next generation
Stage key
KMB-464 (seviteronel) is Kembi's lead small molecule program targeting androgen receptor signalling, which is a key trigger of cancer cell plasticity and therapy resistance in metastatic triple-negative breast cancer.
The current 4Cast Phase 2 clinical trial is evaluating KMB-464 in patients with mTNBC, assessing efficacy in combination with standard of care chemotherapy, where plasticity-driven resistance is a primary mechanism of treatment failure.
Latest interim resultsDevelopment timeline
Preclinical validation
Target identification & compound optimisation
Phase 1 dose escalation — Complete
Safety, tolerability & PK/PD
Phase 2 — Ongoing
Efficacy in mTNBC, plus standard of care
Phase 2 expansion
Additional indications and combinations
KMB-464 Program Overview
Current Stage
Phase 2
Lead Indication
mTNBC
Modality
Small Molecule
The plasticity mechanisms targeted by Kembi's programs are conserved across cancer types. Our platform approach means that insights from KMB-464 in mTNBC directly inform development across multiple dimensions.
Androgen receptor signalling drives plasticity across multiple tumour types. KMB-464 targets this mechanism in mTNBC, with AR positivity shared across a significant proportion of other solid tumours.
Seviteronel's mechanism of blocking AR-driven plasticity is compatible with combination approaches across multiple therapy classes. Clinical learnings from KMB-464 inform rational combination strategies across the portfolio.
KMB-233 targets a confidential plasticity mechanism, representing Kembi's next-generation program. Insights from KMB-464 directly inform target selection and compound design for novel entries in the plasticity pathway.
We welcome conversations with aligned partners and investors.